Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001104659-25-040183
Filing Date
2025-04-28
Accepted
2025-04-28 16:05:36
Documents
18
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A enzn-20241231x10ka.htm   iXBRL 10-K/A 289247
2 EXHIBIT 19.1 enzn-20241231xex19d1.htm EX-19.1 85322
3 EXHIBIT 31.1 enzn-20241231xex31d1.htm EX-31.1 5373
7 GRAPHIC enzn-20241231xex19d1001.jpg GRAPHIC 5259
  Complete submission text file 0001104659-25-040183.txt   728464

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA enzn-20241231.xsd EX-101.SCH 3651
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE enzn-20241231_lab.xml EX-101.LAB 26127
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE enzn-20241231_pre.xml EX-101.PRE 17332
21 EXTRACTED XBRL INSTANCE DOCUMENT enzn-20241231x10ka_htm.xml XML 14786
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-12957 | Film No.: 25880263
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)